Mp74-08 68gapsma Pet/Ct vs. Mpmri in Patients With Suspicion of Prostate Cancer and Previous Negative Biopsy: Results of the Prospet-Bx Trial

You have accessJournal of UrologyProstate Cancer: Detection free-to-total PSA ratio 7.48 (AUC 0.756; 95%CI 0.633-0.855) and SUVratio >2.79 (AUC 0.748; 95%CI 0.624-0.848). PI-RADS, Primary score, SUVmax and SUVratio proved significantly associated to biopsy results. When combining 68GaPSMA PET/CT with mpMRI data, the detection rate was 90% for csPCa, and the combination of both modalities could spare 96% of unnecessary re-biopsies. CONCLUSIONS: In these interim results, 68GaPSMA PET/CT parameters predicts biopsy results as mpMRI in patients candidate to rebiopsy; the combination of both modalities can spare most unnecessary re-biopsies, by granting a 90% detection rate for csPCa. Source of Funding: The study was financially supported by the Italian Ministry of Health (Ministero della Salute) with the Grant GR-2018-12366240 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1196 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Vittorio Fasulo More articles by this author Davide Maffei More articles by this author Paola Arena More articles by this author Pier Paolo Avolio More articles by this author Luca Disconzi More articles by this author Piergiuseppe Colombo More articles by this author Alberto Rosario Saita More articles by this author Rodolfo Fausto Hurle More articles by this author Giorgio Ferruccio Guazzoni More articles by this author Luca Balzarini More articles by this author Marcello Rodari More articles by this author Paolo Casale More articles by this author Nicolò Maria Buffi More articles by this author Massimo Lazzeri More articles by this author Egesta Lopci More articles by this author Giovanni Lughezzani More articles by this author Expand All Advertisement PDF downloadLoading ...